Oncology-focused biotechnology company ADC Therapeutics has doubled its presence at Imperial College’s I-HUB campus in White City, London.
The company has taken circa 12,000 sq ft on the eight floor of the building, bringing its total footprint at the campus to around 24,000 sq ft.
John Anderson, chief investment officer at Imperial College London, said: “Seeing great companies grow at I-HUB is a mark of success that endorses the value of Imperial’s White City Campus and the White City Innovation District eco-system. By supporting ADC Therapeutics strategic growth, we know that they will now accelerate discovery and that advances society. That is at the heart of what I-HUB and the eco-system needs to do.”
Patrick van Berkel, chief scientific officer at ADC Therapeutics, added: “We are excited to expand our research facilities at White City as we work to develop new therapies to treat patients with cancer who have limited treatment options. Our researchers appreciate the support of the team at I-HUB and we look forward to a continued partnership as we endeavour to make a difference in the lives of patients worldwide.”
Paddy Shipp, director – head of UK life sciences agency at JLL, which acts for Imperial College, said: “We’ve seen good demand from life science companies choosing to take space in London and with White City being a key innovation hub in the city, this has received high levels of interest. ADC Therapeutics expanding their presence at the site is a vote of confidence for White City as a key life science cluster.”
